CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

Nature Communications

Volumn 7, Issue , 2016, Pages

  Jacoby, Elad ^a,e   Nguyen, Sang M ^a   Fountaine, Thomas J ^a   Welp, Kathryn ^a   Gryder, Berkley ^a   Qin, Haiying ^a   Yang, Yinmeng ^a   Chien, Christopher D ^a   Seif, Alix E ^b,c   Lei, Haiyan ^a   Song, Young K ^a   Khan, Javed ^a   Lee, Daniel W ^a   Mackall, Crystal L ^a   Gardner, Rebecca A ^d,e   Jensen, Michael C ^d,f   Shern, Jack F ^a   Fry, Terry J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; TRANSCRIPTION FACTOR PAX5; CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RECURRENCE; CELL LINEAGE; CELL PLASTICITY; CONTROLLED STUDY; GENE DELETION; GENOMICS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; T LYMPHOCYTE; ANIMAL; BONE MARROW CELL; CELL CLONE; CHROMATIN; GENE EDITING; GENETIC EPIGENESIS; GENOME; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; RECURRENT DISEASE; TUMOR CELL LINE;

MURINAE;

ANIMALS; CELL LINE, TUMOR; CELL LINEAGE; CELL PLASTICITY; CHROMATIN; CLONE CELLS; EPIGENESIS, GENETIC; GENE EDITING; GENOME; MICE, KNOCKOUT; MYELOID CELLS; PHENOTYPE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE;

EID: 84979901487     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12320     Document Type: Article

References (62)

1. Vardiman J. W., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951 (2009
2. Inaba, H., Greaves, M., & Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943-1955 (2013
3. Hunger, S. P., & Mullighan, C. G. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood 125, 3977-3988 (2015
4. Meyers, S. C., & Levine, R. L. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 15, e382-e394 (2014
5. Greaves, M. F., & Wiemels, J. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer 3, 639-649 (2003
6. Mullighan C. G., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377-1380 (2008
7. Shlush L. I., et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014
8. Stass S., et al. Lineage switch in acute leukemia. Blood 64, 701-706 (1984
9. Gerr, H., et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br. J. Haematol. 149, 84-92 (2010
10. Rossi J. G., et al. Lineage switch in childhood acute leukemia: An unusual event with poor outcome. Am. J. Hematol. 87, 890-897 (2012
11. Slamova L., et al. CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia 28, 609-620 (2014
12. Delia D., et al. Mixed-lineage leukemias and phenotypic shifts occurring in relapsed cases of acute T lymphoblastic lymphomas. Leukemia 2, 192S-197S (1988
13. Ciolli S., et al. Mixed acute leukemia with genotypic lineage switch: a case report. Leukemia 7, 1061-1065 (1993
14. Shende A., et al. A de novo lineage switch from B-cell acute lymphoblastic leukemia to acute myelocytic leukemia: a case report. Am. J. Hematol. 50, 75-77 (1995
15. Fujisaki H., et al. Lineage switch in childhood leukemia with monosomy 7 and reverse of lineage switch in severe combined immunodeficient mice. Exp. Hematol. 27, 826-833 (1999
16. Lounici A., et al. Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia: report of an adult case and review of the literature. Am. J. Hematol. 65, 319-321 (2000
17. Boeckx N., et al. An inv(16)(p13q22) positive acute myeloid leukaemia relapsing as acute precursor B-cell lymphoblastic leukaemia. Haematologica 89, ECR28 (2004
18. Jiang J.-G., et al. Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4; 11) and t(1; 6) translocations and JH gene rearrangement. Leuk. Lymphoma 46, 1223-1227 (2005
19. Stasik, C., Ganguly, S., Cunningham, M. T., Hagemeister, S., & Persons, D. L. Infant acute lymphoblastic leukemia with t(11; 16)(q23; p13.3) and lineage switch into acute monoblastic leukemia. Cancer Genet. Cytogenet. 168, 146-149 (2006
20. Dorantes-Acosta, E., & Pelayo, R. Lineage switching in acute leukemias: a consequence of stem cell plasticity?. Bone Marrow Res. 2012, 1-18 (2012
21. Sadelain, M., Brentjens, R., & Rivie're, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388-398 (2013
22. Mackall, C. L., Merchant, M. S., & Fry, T. J. Immune-based therapies for childhood cancer. Nat. Rev. Clin. Oncol. 11, 693-703 (2014
23. Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635 (2014
24. Kochenderfer J. N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102 (2010
25. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011
26. Davila M. L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014
27. Lee, D W., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet 385 517-528 (2015
28. Maude S. L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014
29. Kochenderfer J. N., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2014
30. Sotillo E., et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282-1295 (2015
31. Del Nagro C. J., et al. CD19 function in central and peripheral B-cell development. Immunol. Res. 31, 119-131 (2005
32. Chung E. Y., et al. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J. Clin. Invest. 122, 2257-2266 (2012
33. Bijl, J., Sauvageau, M., Thompson, A., & Sauvageau, G. High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev. 19, 224-233 (2005
34. Shand, J. C., Qin, H., Nasholm, N., Capitini, C. M., & Fry, T. J. Minor antigen distribution predicts site-specific graft-versus-Tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells. Biol. Blood Marrow Transplant. 20, 26-36 (2014
35. Jacoby E., et al. Murine allogeneic CD19 CAR T-cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361-1370 (2016
36. Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P., & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875-3886 (2010
37. Lin, Y. C., et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat. Immunol. 11, 635-643 (2010
38. Cobaleda, C., Schebesta, A., Delogu, A., & Busslinger, M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8, 463-470 (2007
39. Yu D., et al. Oscillation between B-lymphoid and myeloid lineages in Mycinduced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101, 1950-1955 (2003
40. Cobaleda, C., Jochum, W., & Busslinger, M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449, 473-477 (2007
41. Zeng, X. X., Zhang, H., Hardy, R. R., & Wasserman, R. The fetal origin of B-precursor leukemia in the E-mu-ret mouse. Blood 92, 3529-3536 (1998
42. Seif, A., Barrett, D., Milone, M., & Brown, V. Long-Term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood 114, 2459-2467 (2009
43. Leddin M., et al. Two distinct auto-regulatory loops operate at the PU. 1 locus in B cells and myeloid cells. Blood 117, 2827-2839 (2011
44. Guo, H., Ma, O., Speck, N. A., & Friedman, A. D. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis. Blood 119, 4408-4418 (2012
45. Hardy, R. R. B-cell commitment: deciding on the players. Curr. Opin. Immunol. 15, 158-165 (2003
46. Nutt, S., Heavy, B., Rolnik, A., & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556-562 (1999
47. Rolink, A. G., Nutt, S. L., Melchers, F., & Busslinger, M. Long-Term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors. Nature 401, 603-606 (1999
48. Mikkola, I., Heavy, B., Horcher, M., & Busslinger, M. Reversion of B cell commitment upon loss of Pax5 expression. Science 297, 110-113 (2002
49. Evans A. G., et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br. J. Haematol. 171, 205-209 (2015
50. Gardner R., et al. Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy. Blood 127, 2406-2410 (2016
51. Rayes, A., McMasters, R. L., & O?Brien, M. M. Lineage switch in MLLrearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer 63, 1113-1115 (2016
52. Jacoby, E., Chien, C. D., & Fry, T. J. Murine models of acute leukemia: important tools in current pediatric leukemia research. Front. Oncol. 4, 95 (2014
53. Iwamoto T., et al. Preferential development of pre-B lymphomas with drastically down-regulated N-myc in the E mu-ret transgenic mice. Eur. J. Immunol. 21, 1809-1814 (1991
54. Wasserman, R., Zeng, X. X., & Hardy, R. R. The evolution of B precursor leukemia in the Emu-ret mouse. Blood 92, 273-282 (1998
55. Nechanitzky R., et al. Transcription factor EBF1 is essential for the maintenance of B cell identity and prevention of alternative fates in committed cells. Nat. Immunol. 14, 867-875 (2013
56. Dang J., et al. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood 125, 3609-3617 (2015
57. Duque-Afonso J., et al. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia. J. Clin. Invest. 125, 3667-3680 (2015
58. Andersson A. K., et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330-337 (2015
59. Bernt, K., & Armstrong, S. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology 4, 354-360 (2011
60. Horton S. J., et al. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia 27, 1116-1126 (2013
61. Krivtsov A. V., et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 27, 852-860 (2013
62. deBoer, J., Walf-Vorderwülbecke, V., & Williams, O. In focus: MLL-rearranged leukemia. Leukemia 27, 1224-1228 (2013